Personalised Acceptance and Commitment Therapy (PACT) for Parkinson's Disease

Acceptability and feasibility randomized controlled trial of a digital psychological support intervention for people with Parkinson’s disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN65177345

Enrollment

Registered

2023-08-21

Start date

2023-09-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease Nervous System Diseases Parkinson disease

Interventions

The intervention is a digital app that contains sessions based on Acceptance and Commitment Therapy (ACT). Randomisation will follow a 2:1 ratio stratified by disease duration and baseline levels of p

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 years and above 2. Self-reported diagnosis of Parkinson's 3. Lives in the UK 4. Has access to computer/tablet/smartphone and the internet 5. Is able to read and communicate in English 6. Be stable on anti-depressants or anxiolytics if taken- stable dose for a minimum of 1 month 7. Mild-to-moderate levels of distress determined by a score between 3-8 on the PHQ4

Exclusion criteria

Exclusion criteria: 1. Severe cognitive impairment as determined by a score of 20 or above on the 6-item Cognitive Impairment Test (Katzman, Brown & Fuld, 1983) 2. Psychiatric conditions (e.g., psychosis, drug/ alcohol addiction) that can potentially risk failure in the treatment or limit participation in the course

Design outcomes

Primary

Measure	Time frame
1. Recruitment and retention rate: proportion of people identified as eligible after screening, proportion of eligible people randomized and consented to the study, proportion of people who completed the baseline and end-point assessments 2. Intervention engagement: number of times logged on to the app and number of sessions completed during the 4-week trial period 3. Intervention acceptability measured by a questionnaire and interviews based on the Theoretical Framework of Acceptability domains at the end of the trial period	—

Measure

Time frame

1. Recruitment and retention rate: proportion of people identified as eligible after screening, proportion of eligible people randomized and consented to the study, proportion of people who completed the baseline and end-point assessments 2. Intervention engagement: number of times logged on to the app and number of sessions completed during the 4-week trial period 3. Intervention acceptability measured by a questionnaire and interviews based on the Theoretical Framework of Acceptability domains at the end of the trial period

—

Secondary

Measure	Time frame
1. Depression measured using the PHQ-9 at 4 weeks 2. Anxiety measured using the GAD-7 at 4 weeks 3. Quality of life measured by the PDQ-8 at 4 weeks 4. Acceptance and commitment therapy processes measured by the AAQ-2, Experiences questionnaire and CAQ-8 at 4 weeks 5. Healthcare utilisation measured by the Client service receipt inventory (CSRI) at baseline and 4 weeks	—

Countries

England, Northern Ireland, Scotland, United Kingdom, Wales

Contacts

Public ContactCathryn Pinto

cathryn.pinto@city.ac.uk+44 (0)20 7040 4041

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026